Asymchem (6821.HK) 3Q26 Earnings review: 4Q delivery key to restoring visibility; FY27 acceleration intact

GS View: We believe the recent share price weakness reflects a combination of broader market de-risking, renewed concerns around potential US restrictions on China biotech BD, and company-specific concerns around earnings visibility after revenue delivery was affected by shipment timing for two consecutive quarters. We see 4Q26 execution as particularly important for restoring investor confidence in near-term earnings visibility, and remain constructive on Asymchem's strategy of accelerating capex into new growth areas, particularly peptides and ADCs. 3Q26 revenue was Rmb1,788mn, +24% yoy, below GSe mainly due to shipment timing; Emerging Services revenue rose 18% yoy while small-molecule revenue grew 28%;